Allogene Therapeutics Stock Market Value
| ALLO Stock | USD 1.91 0.16 7.73% |
| Symbol | Allogene |
Allogene Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Allogene Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Allogene Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Allogene Therapeutics.
| 12/30/2022 |
| 12/19/2024 |
If you would invest 0.00 in Allogene Therapeutics on December 30, 2022 and sell it all today you would earn a total of 0.00 from holding Allogene Therapeutics or generate 0.0% return on investment in Allogene Therapeutics over 720 days. Allogene Therapeutics is related to or competes with Heron Therapeuti, Annexon, Sangamo Therapeutics, Beam Therapeutics, Sana Biotechnology, Caribou Biosciences, and Editas Medicine. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineere... More
Allogene Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Allogene Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Allogene Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 19.85 | |||
| Value At Risk | (8.09) | |||
| Potential Upside | 8.99 |
Allogene Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Allogene Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Allogene Therapeutics' standard deviation. In reality, there are many statistical measures that can use Allogene Therapeutics historical prices to predict the future Allogene Therapeutics' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.20) |
Allogene Therapeutics Backtested Returns
Allogene Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0944, which signifies that the company had a -0.0944% return per unit of risk over the last 3 months. Allogene Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Allogene Therapeutics' Standard Deviation of 4.98, risk adjusted performance of (0.07), and Mean Deviation of 4.02 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.56, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allogene Therapeutics will likely underperform. At this point, Allogene Therapeutics has a negative expected return of -0.48%. Please make sure to confirm Allogene Therapeutics' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Allogene Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.49 |
Average predictability
Allogene Therapeutics has average predictability. Overlapping area represents the amount of predictability between Allogene Therapeutics time series from 30th of December 2022 to 25th of December 2023 and 25th of December 2023 to 19th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Allogene Therapeutics price movement. The serial correlation of 0.49 indicates that about 49.0% of current Allogene Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.69 |
Allogene Therapeutics lagged returns against current returns
Autocorrelation, which is Allogene Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Allogene Therapeutics' stock expected returns. We can calculate the autocorrelation of Allogene Therapeutics returns to help us make a trade decision. For example, suppose you find that Allogene Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Allogene Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Allogene Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Allogene Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Allogene Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Allogene Therapeutics Lagged Returns
When evaluating Allogene Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Allogene Therapeutics stock have on its future price. Allogene Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Allogene Therapeutics autocorrelation shows the relationship between Allogene Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Allogene Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.68 | DYAI | Dyadic International | PairCorr |
| 0.55 | ESPR | Esperion Therapeutics | PairCorr |
| 0.55 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Allogene Therapeutics Correlation, Allogene Therapeutics Volatility and Allogene Therapeutics Alpha and Beta module to complement your research on Allogene Therapeutics. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Allogene Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.